. Show Affiliations »
Abstract
Entities: Chemical
Mesh: See more » Antibodies, Monoclonal/therapeutic useAntineoplastic Agents, Immunological/therapeutic useClinical Trials, Phase III as TopicDrug ApprovalHumansSarcoma/drug therapySoft Tissue Neoplasms/drug therapy
Substances: See more » Antibodies, MonoclonalAntineoplastic Agents, Immunologicalolaratumab
Year: 2019 PMID: 31249400 DOI: 10.1038/s41571-019-0246-9
Source DB: PubMed Journal: Nat Rev Clin Oncol ISSN: 1759-4774 Impact factor: 66.675